Vicore Pharma Holding 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ahmed Mousa

최고 경영자

SEK 6.3m

총 보상

CEO 급여 비율	23.5%
CEO 임기	1.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	1.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ahmed Mousa 의 보수는 Vicore Pharma Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 196m
Jun 30 2024	n/a	n/a	-SEK 200m
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 6m	SEK 1m	-SEK 311m

보상 대 시장: Ahmed 의 총 보상 ($USD 580.42K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 852.77K ).

보상과 수익: Ahmed 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Ahmed Mousa (39 yo)

1.8yrs

테뉴어

SEK 6,339,074

보상

Mr. Ahmed S. Mousa, J. D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ahmed Mousa	Chief Executive Officer	1.8yrs	SEK 6.34m	데이터 없음
Hans Jeppsson	Chief Financial Officer	7.4yrs	데이터 없음	0.0021% € 3.6k
Mikael Nygård	Vice President of Operations & Corporate Strategy	less than a year	데이터 없음	0.0017% € 2.9k
Johan Raud	Chief Scientific Officer	6.8yrs	데이터 없음	0.10% € 170.0k
Nina Carlen	Chief Administrative Officer	15.8yrs	데이터 없음	0.010% € 17.4k
Megan Richards	VP of Investor Relations	less than a year	데이터 없음	데이터 없음
Jessica Shull	Head of Digital Therapeutics & Director of Digital Innovation	3.5yrs	데이터 없음	데이터 없음
Asa Magnusson	Chief Engagement & Commercial Officer	3.1yrs	데이터 없음	데이터 없음
Bertil Lindmark	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Jimmie Hofman	Vice President of Business Development	less than a year	데이터 없음	데이터 없음
Helen Barker	VP & Head of CMC	less than a year	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: 6Y4 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jacob Gunterberg	Independent Director	no data	SEK 886.00k	0.0027% € 4.6k
Michael Buschle	Director	1.5yrs	SEK 405.00k	데이터 없음
Ann Barbier	Independent Director	less than a year	데이터 없음	데이터 없음
Yasir Al-Wakeel	Independent Director	less than a year	데이터 없음	데이터 없음
Hans J. G. C. Schikan	Independent Chairman	6.3yrs	SEK 450.00k	0.0017% € 2.9k
Elisabeth Bjork	Director	1.5yrs	SEK 405.00k	데이터 없음
Heidi Hunter	Independent Director	4.5yrs	SEK 519.00k	0.0021% € 3.6k

1.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: 6Y4 의 이사회는 경험(평균 재직 기간 1.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Vicore Pharma Holding 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Vicore Pharma Holding AB (publ), Annual General Meeting, May 06, 2025

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Recent updates

Vicore Pharma Holding AB (publ) to Report Q2, 2025 Results on Aug 22, 2025

Vicore Pharma Holding AB (publ), Annual General Meeting, May 06, 2025

New major risk - Shareholder dilution

Vicore Pharma Holding AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 782.138028 million.

Vicore Pharma Holding AB Initiates the Global, Randomized Phase 2B Aspre Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.

Vicore Pharma Holding AB Announces Positive Data from Phase II Study Attract in Patients with Covid-19 Published Online

New 90-day high: €2.82

Vicore Pharma Holding Reports an Expanded Data Analysis to Follow Up the Encouraging Top Line Data from the ATTRACT

Vicore Pharma Holding AB (Publ) Announces Last Patient Last Visit in the Mechanistic Phase II Study with C21 in Systemic Sclerosis

Vicore Pharma Reports Positive Top Line Data from the ATTRACT clinical study in patients with COVID-19

New 90-day low: €1.78

Vicore Pharma Holding AB Recruits the First Patient in the Phase II Proof-Of-Concept Study in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 15, 2021

Vicore Pharma Holding AB (publ) to Report Q2, 2021 Results on Aug 26, 2021

Vicore Pharma Holding AB (Publ) Announces Completion of Patient Enrollment in the Covid-19 Attract Trial

Vicore Pharma Holding AB (publ) Announces Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령